Hypoglycemia or a below normal blood sugar level is a common complication of diabetes. The condition can also arise due to prolonged starvation, certain hormonal disorders such as hypopituitarism and ...

IN the majority of infants with chronic hypoglycemia the specific origin of the disorder cannot be identified. Regardless of etiology, correction of the hypoglycemia is essential to prevent mental ...

The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg (Reuters) - The U.S. Food and Drug Administration ...

School personnel should soon be allowed to administer a new nasal spray used to treat severe hypoglycemia. In 2019, the Food and Drug Administration approved the use of Baqsimi nasal powder, the first ...

Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of ...

Researchers have shown that a targeted treatment they developed is effective at controlling blood sugar in patients with hyperinsulinism (HI), a genetic disease in which the pancreas produces too much ...

Treatment of factitious hypoglycemia, whether it is insulin- or sulfonylurea-induced, takes place in 2 stages. [3] The first stage involves relieving the neuroglycopenic symptoms by restoring the low ...

Glucagon is underused for treating severe hypoglycemia in both emergency and outpatient settings, new research suggests. Findings from an analysis of data on glucagon administration by emergency ...

The submission is supported by three phase 3 trials in adult and pediatric patients that showed dasiglucagon met the primary and all key secondary end points. A New Drug Application (NDA) has been ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology ...

Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access Program REDWOOD CITY, ...

News and commentary from the world of gastroenterology and hepatology ...